Accepting new patients
Ruchika Sangani, MD
(she/her) - Pulmonology
Burbank Pulmonology & Sleep Medicine
|
2625 West Alameda Avenue,
Suite 412,
Burbank, CA
91505
About
Dr. Ruchika Sangani is a pulmonary and critical care medicine physician at UCLA. She is board certified in internal medicine, pulmonary disease, and critical care medicine. Her clinical interests include interstitial lung disease, pulmonary fibrosis, sarciodosis, and asthma.
Dr. Sangani is from Upstate New York and completed her undergraduate studies at Columbia University where she studied engineering and economics. She received her medical degree from Upstate Medical University after which she moved to Boston to complete both her internal medicine and pulmonary and critical care medicine training at Boston Medical Center. She joined the UCLA Division of Pulmonary and Critical Care faculty in September 2024.
Languages
Education
Medical Board Certifications
Critical Care Medicine, American Board of Internal Medicine, 2023
Pulmonary Disease, American Board of Internal Medicine, 2022
Internal Medicine, American Board of Internal Medicine, 2019
Fellowship
Pulmonary Critical Care Medicine, Boston University Medical Center, 2023
Residency
Internal Medicine, Boston University Medical Center, 2019
Degree
MD, SUNY Upstate Medical University, 2016
Locations
San Fernando Valley
Burbank Pulmonology & Sleep Medicine
Burbank Pulmonology & Sleep Medicine
Pulmonology| Sleep Medicine
Fax:818-260-8709
Hospital Affiliations
Ronald Reagan UCLA Medical Center
UCLA Santa Monica Medical Center
Research
Publications
- Sangani R, Lee MM, Xu H, Dupuis J, O'Connor GT. The Upper Limit of Normal Rate of Lung Function Decline in Healthy Adults in the Framingham Heart Study. CHEST Pulm. 2024 Sep;2(3):100058. doi: 10.1016/j.chpulm.2024.100058. Epub 2024 Apr 15. PMID: 39421758; PMCID: PMC11484874.
- Kearney CM, Sangani R, Shankar D, O'Connor GT, Law AC, Walkey AJ, Bosch NA. Comparative Effectiveness of Mepolizumab, Benralizumab, and Dupilumab among Patients with Difficult-to-Control Asthma: A Multicenter Retrospective Propensity-matched Analysis. Ann Am Thorac Soc. 2024 Jun;21(6):866-874. doi: 10.1513/AnnalsATS.202306-566OC. PMID: 38241013; PMCID: PMC11160126.
- Lui JK, Gillmeyer KR, Sangani RA, Smyth RJ, Gopal DM, Trojanowski MA, Bujor AM, Soylemez Wiener R, LaValley MP, Klings ES. A Clinical Decision Tool for Risk Stratifying Patients with Systemic Sclerosis-Related Pulmonary Hypertension. Lung. 2023 Dec;201(6):565-569. doi: 10.1007/s00408-023-00646-2. Epub 2023 Nov 13. PMID: 37957388; PMCID: PMC11037922.
- Vakhshoorzadeh J, Lui JK, Sangani RA, Trojanowski MA, Bujor AM, LaValley MP, Klings ES. Emphysema and interstitial lung disease in systemic sclerosis-related pulmonary hypertension. Respir Med. 2023 Sep;216:107333. doi: 10.1016/j.rmed.2023.107333. Epub 2023 Jun 17. PMID: 37336329; PMCID: PMC10666733.
- Pang B, Kearney L, Maccarone J, Zhang J, Kearney C, Sangani R, Shankar DA, Gillmeyer KR, Law AC, Bosch NA. Association between Early Venous Thromboembolism Prophylaxis, Bleeding Risk, and Venous Thromboembolism among Critically Ill Patients with Thrombocytopenia. Ann Am Thorac Soc. 2023 Jun;20(6):917-920. doi: 10.1513/AnnalsATS.202210-847RL. PMID: 36867519; PMCID: PMC10257036.
- Mesfin N, Sangani R, Shankar DA, Reardon C. New Frontiers in Therapeutics for Interstitial Lung Diseases. Am J Respir Crit Care Med. 2023 Apr 15;207(8):1089-1091. doi: 10.1164/rccm.202206-1035RR. PMID: 36735934; PMCID: PMC10112432.
- Lui JK, Sangani RA, Gillmeyer KR, Vakhshoorzadeh J, Trojanowski MA, Bujor AM, Gopal DM, Wiener RS, LaValley MP, Klings ES. Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension. Cardiovasc Drugs Ther. 2024 Jun;38(3):651-656. doi: 10.1007/s10557-022-07420-1. Epub 2023 Jan 6. Erratum in: Cardiovasc Drugs Ther. 2024 Jun;38(3):657. doi: 10.1007/s10557-023-07431-6. PMID: 36607535; PMCID: PMC10666735.
- Sangani RA, Lui JK, Gillmeyer KR, Trojanowski MA, Bujor AM, LaValley MP, Klings ES. Clinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: Contribution from pulmonary hypertension and interstitial lung disease severity. Pulm Circ. 2022 Oct 1;12(4):e12117. doi: 10.1002/pul2.12117. PMID: 36238967; PMCID: PMC9535436.
- Lui JK, Gillmeyer KR, Sangani RA, Smyth RJ, Gopal DM, Trojanowski MA, Bujor AM, Soylemez Wiener R, LaValley MP, Klings ES. A Multimodal Prediction Model for Diagnosing Pulmonary Hypertension in Systemic Sclerosis. Arthritis Care Res (Hoboken). 2023 Jul;75(7):1462-1468. doi: 10.1002/acr.24969. Epub 2023 Jan 18. PMID: 35678779; PMCID: PMC9732142.
- Lui JK, Sangani RA, Chen CA, Bujor AM, Trojanowski MA, Gopal DM, LaValley MP, Soylemez Wiener R, Klings ES. Prognostic Value of Cardiac Axis Deviation in Systemic Sclerosis-Related Pulmonary Hypertension. Arthritis Care Res (Hoboken). 2022 Jul;74(7):1219-1226. doi: 1002/acr.24724. Epub 2022 Apr 5. PMID: 34085410; PMCID: PMC8639831.
Insurance
- Aetna
- Anthem Blue Cross
- Blue Shield of California
- Centivo
- Cigna
- First Health
- Health Net of California
- Interplan (part of HealthSmart)
- L.A. Care
- Medicare Advantage
- MultiPlan
- UFCM Health System
- Prime Health Services
- Private Healthcare Systems (PHCS)
- TRICARE
- UnitedHealthcare
The list of health care plans above may not be comprehensive and could change.
Please contact your benefits coordinator or health insurance company directly to verify coverage.
Visit our health insurance information page for more details.